Delivering optimal care for inflammatory bowel disease patients in Scotland in 2014

被引：0
作者：
Gaya, Daniel R. [1 ]
机构：
[1] Glasgow Royal Infirm, Gastroenterol Unit, Glasgow G4 0SF, Lanark, Scotland
来源：
SCOTTISH MEDICAL JOURNAL | 2014年 / 59卷 / 02期
关键词：
Crohn's disease; inflammatory bowel disease; ulcerative colitis; CROHNS-DISEASE; FECAL CALPROTECTIN; THIOPURINE METHYLTRANSFERASE; AZATHIOPRINE THERAPY; COST-EFFECTIVENESS; SMOKING-CESSATION; OUTCOMES; METHOTREXATE; ALLOPURINOL; MANAGEMENT;
D O I：
10.1177/0036933014531540
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, present an ever increasing burden to the healthcare systems in the Western world. Scotland in particular has seen a significant increase in both diseases, particularly Crohn's disease. It is thus of paramount importance that secondary care services within Scotland are equipped to cope with this increased demand at a time when the treatment options are broadening, patients expectations are increasing and healthcare budgets face major restriction. This article outlines some aspects of optimal delivery of an IBD service in secondary care.
引用
收藏
页码：130 / 135
页数：6
相关论文
共 43 条
  • [31] Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease
    Roseth, AG
    Aadland, E
    Grzyb, K
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2004, 39 (10) : 1017 - 1020
  • [32] Patients with Crohn's disease are unaware of the risks that smoking has on their disease
    Ryan, WR
    Ley, C
    Allan, RN
    Keighley, MRB
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (05) : 706 - 711
  • [33] A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease
    Sack, C.
    Phan, V. A.
    Grafton, R.
    Holtmann, G.
    van Langenberg, D. R.
    Brett, K.
    Clark, M.
    Andrews, J. M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2012, 6 (03) : 302 - 310
  • [34] The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and paediatric gastroenterologists
    Sebastian, Shaji
    Jenkins, Huw
    McCartney, Sarah
    Ahmad, Tariq
    Arnott, Ian
    Croft, Nick
    Russell, Richard
    Lindsay, James O.
    [J]. JOURNAL OF CROHNS & COLITIS, 2012, 6 (08) : 830 - 844
  • [35] Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
    Sparrow, Miles P.
    Hande, Scott A.
    Friedman, Sonia
    Cao, Dingcai
    Hanauer, Stephen B.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (02) : 209 - 214
  • [36] Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
    Sparrow, MP
    Hande, SA
    Friedman, S
    Lim, WC
    Reddy, SI
    Cao, D
    Hanauer, SB
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (05) : 441 - 446
  • [37] Nicotine replacement therapy for smoking cessation (Review)
    Stead, L. F.
    Perera, R.
    Mant, D.
    Lancaster, T.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
  • [38] Group behaviour therapy programmes for smoking cessation
    Stead, LF
    Lancaster, T
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [39] The IBD Standards Group, 2010, SERV STAND HEALTHC P
  • [40] Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
    Tibble, JA
    Sigthorsson, G
    Bridger, S
    Fagerhol, MK
    Bjarnason, I
    [J]. GASTROENTEROLOGY, 2000, 119 (01) : 15 - 22
12345